IGF2 and glioblastoma: In the TCGA and CGGA cohorts, GBM with high expressions of IGF2 (HR = 1.57; 1.85), RETN (2.24; 2.13), C3AR1 (1.83; 2.16), CLCF1 (1.76; 2.44), NTRK1 (1.58; 2.50), OSMR (3.72; 2.37), KCNN4 (2.36; 2.62), SLC18A3 (1.88; 1.87) or HTR7 (1.74; 1.79) had significant shorter OS, indicating predictions for a worse prognosis.